Edited by Peter Hillerberg1 min readStories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
TD Cowen ran a sweep through life sciences stocks, lifting targets across four names simultaneously. The most aggressive call landed on RVTY. Revvity's target jumped from $130 to $175, a 35% lift, with Cowen keeping a Buy rating. TMO Thermo Fisher Scientific also got a raise, from $675 to $760, and ILMN Illumina climbed from $210 to $270 despite only a Hold rating.
DDOG Datadog drew a separate upgrade from Barclays. Raimo Lenschow pushed the target to $300 from $290, sticking with Buy. Datadog carries 42 Buy ratings in the consensus, the most bullish skew in the batch.
The sharpest downgrade belonged to APP AppLovin. Morgan Stanley trimmed its target from $450 to $400, a $50 cut on a stock worth over $82bn. The firm kept its Buy rating, but the direction of travel is notable for a name that had been a Wall Street darling.
In real estate, Barclays split its REIT views. HST Host Hotels got a target raise to $25. DOC Healthpeak Properties saw its target cut from $24 to $21, a 13% reduction.
CBRE rounded out the session with a consensus target trim. Twelve analysts hold Buy ratings, but the average target edged lower to $179.67.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
